MedRegen entered into clinical development and initiated its phase I trial with MRG-001 in the US in healthy volunteers and progressed to a multicenter international phase 2 trial in severely and critically ill COVID19 patients.
MedRegen entered into clinical development and initiated its phase I trial with MRG-001 in the US in healthy volunteers and progressed to a multicenter international phase 2 trial in severely and critically ill COVID19 patients.